Viewing

CSI Deputy Director, Prof Chng Wee Joo, Appointed Provost’s Chair at NUSMed

CSI extends our heartiest congratulations to our Deputy Director, Prof Chng Wee Joo, who has been appointed Provost’s Chair at the Yong Loo Lin School of Medicine, NUS! Prof Chng, who is also Director of the National University Cancer Institute, Singapore (NCIS), has made significant contributions towards research on hematologic malignancies such as Multiple Myeloma

Triple negative breast cancer in Asia: An insider’s view. (Cancer Treat Rev, Nov 2017)

Wang C1, Kar S1, Lai X1, Cai W1, Arfuso F2, Sethi G3, Lobie PE4, Goh BC5, Lim LHK6, Hartman M7, Chan CW8, Lee SC5, Tan SH9, Kumar AP10. Author information 1 Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

CSI Research Scientist Awarded the ASH Abstract Achievement Award!

Congratulations to Dr Xie Zhigang, Research Scientist from Prof Chng Wee Joo’s team, who recently received a travel award from the American Society of Hematology (ASH) to attend and present his research titled “MMSET I Acts As an Oncoprotein and Regulates GLO1 Expression in T(4;14) Multiple Myeloma Cells” at the 59th ASH Annual Meeting and

XIAP inhibition sensitizes acute myeloid leukemia cells response to TRAIL and chemotherapy through potentiated induction of pro-apoptotic machinery. (Mol Oncol, Oct 2017)

Zhou J1,2, Lu X1, Tan TZ1,3, Chng WJ1,2,4. Author information 1 Cancer Science Institute of Singapore National University of Singapore14 Medical Drive, Centre for Translational Medicine, Singapore, 117599, Republic of Singapore. 1 Department of Medicine, Yong Loo Lin School of Medicine National University of Singapore, Singapore, 119074, Republic of Singapore. 1 Translational Centre for Development

EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes. (Haematologica, Nov 2017)

Ng SB1, Chung TH2, Kato S3, Nakamura S3, Takahashi E4, Ko YH5, Khoury JD6, Yin CC6, Soong R7, Jeyasekharan AD2, Hoppe MM2, Selvarajan V8, Tan SY9, Lim ST10, Ong CK11, Nairismägi ML11, Maheshwari P12, Choo SN8, Fan S8, Lee CK8, Chuang SS13, Chng WJ14. Author information 1 Department of Pathology, Yong Loo Lin School of

The roles of ubiquitin modifying enzymes in neoplastic disease. (Biochim Biophys Acta, Sept 2017)

Kumari N1, Jaynes PW2, Saei A3, Iyengar PV2, Richard JLC2, Eichhorn PJA4. Author information 1 Cancer Science Institute of Singapore, National University of Singapore, 117599, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore. 2 Cancer Science Institute of Singapore, National University of Singapore, 117599, Singapore. 3 Cancer

AACR-CSI Partnership 2017

CSI Singapore is proud to collaborate with American Association for Cancer Research (AACR) for Frontiers in Cancer Science (FCS) 2017! This partnership will open doors to great opportunities for both AACR and CSI Singapore. Both organizations’ missions and visions align in aiming to deliver outstanding research leading to better cancer prevention, diagnosis and treatment. CSI